N01.7 Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis

Name of the Condition

• Rapidly Progressive Nephritic Syndrome with Diffuse Crescentic Glomerulonephritis
• ICD-10 Code: N01.7

Summary

Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis is a severe kidney disorder marked by rapid loss of renal function due to extensive inflammation and damage to the glomeruli, the kidney's filtering units. The term "diffuse crescentic" refers to widespread glomerular injury with crescent formation, a hallmark of aggressive disease. Clinical features typically include hematuria (blood in urine), proteinuria (excess protein in urine), hypertension, and a swift decline in kidney function, often progressing to acute kidney injury within weeks. Urgent intervention is critical to prevent irreversible damage.

Causes

The condition is primarily driven by immune-mediated damage to the glomeruli, where the body’s immune system attacks kidney tissue. This may result from autoimmune diseases (such as anti-glomerular basement membrane disease, vasculitis, or lupus), infections (e.g., post-infectious processes), or exposure to certain medications. In some cases, the underlying trigger remains idiopathic, but the rapid progression reflects a severe immune response.

Risk Factors

• Autoimmune conditions: Diseases like granulomatosis with polyangiitis, lupus, or anti-glomerular basement membrane disease.
• Infections: Recent bacterial or viral infections that may trigger immune responses.
• Medications: Use of drugs known to induce glomerular injury (e.g., certain antibiotics or NSAIDs).
• Genetic predisposition: Family history of kidney disease or autoimmune disorders.

Symptoms

• Hematuria (visible or microscopic blood in urine).
• Proteinuria (excess protein in urine, potentially causing foamy urine).
• Hypertension (high blood pressure).
• Rapid decline in kidney function (e.g., rising serum creatinine levels).
• Edema (swelling, particularly in the legs or face).
• Fatigue or malaise.

Diagnosis

Diagnosis involves a combination of clinical evaluation, laboratory tests, and imaging. Urinalysis typically shows hematuria and proteinuria. Blood tests assess kidney function (e.g., serum creatinine, BUN) and immune markers (e.g., ANCA, anti-GBM antibodies). A kidney biopsy is essential to confirm diffuse crescentic glomerulonephritis and identify the underlying cause. Imaging (e.g., ultrasound) may evaluate kidney size and structure.

Treatment Options

Treatment focuses on suppressing the immune response to halt glomerular damage. This often includes high-dose corticosteroids, immunosuppressive agents (e.g., cyclophosphamide), and plasma exchange (plasmapheresis) for severe cases. Supportive care addresses complications like hypertension or fluid overload. Underlying causes (e.g., infections or autoimmune diseases) are managed concurrently.

Prognosis and Follow-Up

Prognosis depends on the speed of diagnosis and treatment. Early intervention improves outcomes, but some patients may progress to end-stage renal disease requiring dialysis or transplantation. Regular follow-up monitors kidney function, blood pressure, and treatment response. Long-term management may involve ongoing immunosuppression and lifestyle adjustments.

Complications

• Acute kidney injury or end-stage renal disease.
• Hypertension (persistent or worsening).
• Pulmonary hemorrhage (in anti-GBM disease).
• Infection risk from immunosuppressive therapy.
• Cardiovascular complications (e.g., heart failure).

Lifestyle & Prevention

• Manage underlying conditions (e.g., autoimmune diseases) with medical guidance.
• Avoid nephrotoxic medications (e.g., certain NSAIDs) unless prescribed.
• Maintain a balanced diet and hydration, as advised by a healthcare provider.
• Monitor blood pressure and kidney function regularly if at risk.

When to Seek Professional Help

Seek immediate medical attention for symptoms like persistent hematuria, severe swelling, or sudden changes in urine output. Urgent care is critical if kidney function declines rapidly or if hypertension becomes uncontrolled.

Tips for Medical Coders

Document the presence of diffuse crescentic glomerulonephritis (confirmed via biopsy) and any associated autoimmune markers (e.g., ANCA, anti-GBM) to support the N01.7 code. Ensure clinical correlation with rapid renal function decline and exclude other nephritic syndromes. Code assignment should reflect the specific pathological and clinical findings.